|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The variant allele of the Gly482Ser polymorphism in peroxisome proliferator-activated receptor-gamma co-activator-1alpha (PPARGC1A or PGC1alpha), a critical determinant of skeletal muscle metabolism, has been associated with obesity and type 2 diabetes.
|
16474966 |
2006 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Our study aimed to analyze whether the expression of PPARγ mRNA in subcutaneous adipocyte tissue correlates with Pro12Ala PPARγ2 polymorphism in the obesity context.
|
23315125 |
2013 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Obesity and Pro12Ala Polymorphism of Peroxisome Proliferator-Activated Receptor-Gamma Gene in Healthy Adults: A Systematic Review and Meta-Analysis.
|
26361038 |
2015 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We investigated a possible association of PPARg2 Pro12Ala polymorphism with obesity and myocardial infarction in Han Chinese in Hohhot, Inner Mongolia, China.
|
22653647 |
2012 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The combined results showed that PPAR-γ Pro12Ala polymorphism was associated with the obesity risk (Ala vs.
|
25502405 |
2015 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The single nucleotide polymorphisms (SNPs) of the above genes, such as GNB3-C825T, ADRB3-Trp64Arg, UCP2-3'UTR 45 bp del/ins, and PPARγ-Pro12Ala, are associated with obesity and body mass index.
|
24827746 |
2014 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Previous studies have sought to associate the Pro12Ala variant of the peroxisome proliferator-activated receptor gamma2 (PPARG2) gene with type 2 diabetes, insulin resistance, and obesity, with controversial results.
|
17985660 |
2007 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the Pro12Ala mutation in PPARgamma is not associated with either diabetes or obesity and may not be an important determinant of obesity or diabetes in Korean subjects.
|
10843155 |
2000 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the higher frequency of the C-->T substitution in exon 6 of the PPAR-gamma gene in PCOS women suggests that it plays a role in the complex pathogenetic mechanism of obesity in PCOS, whereas the Pro(12)Ala polymorphism does not seem to affect BMI in PCOS women.
|
14671186 |
2003 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The Pro12Ala polymorphism in exon B of peroxisome proliferator-activated receptor gamma 2 (PPAR gamma 2) gene has been related to obesity, insulin resistance, and risk of type 2 diabetes.
|
14981210 |
2004 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
To further elucidate the role of genetics in obesity onset, we performed a candidate-gene association study in a young and sportive Italian population by testing the association of functional polymorphisms in ACE (rs4646994), FTO (rs9939609), MC4R (rs17782313) and PPARG (rs1801282) genes with body mass index (BMI) and waist-to-height ratio (WHtR).
|
28090739 |
2017 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Paradoxically, in utero exposure of Y114F PCNA females to DEHP led to a significant increase in body mass and was associated with augmented expression of PPARγ, a critical regulator of obesity, compared to WT controls.
|
28915506 |
2017 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We tested whether a targeted reduction in hepatic peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), which has been shown to occur with obesity, had a negative impact on the metabolic effects of FGF21.
|
29215172 |
2018 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Novel variants in the putative peroxisome proliferator-activated receptor {gamma} promoter and relationships with obesity in men.
|
15976135 |
2005 |
|
Obesity
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The peroxisome proliferator-activated receptor gamma 2 Pro12Ala mutation is associated with early onset extreme obesity and reduced fasting glucose.
|
10873398 |
2000 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
CTD_human |
Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.
|
11089532 |
2000 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
<i>PPARG-LYPLAL1</i> Multi-Allelic Combination Associated with Obesity and Overweight in Mexican Adolescent Females.
|
27773974 |
2016 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Peroxisome Proliferator-Activated Receptor Gamma in Obesity and Colorectal Cancer: the Role of Epigenetics.
|
28878369 |
2017 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Interaction between Calpain 5, Peroxisome proliferator-activated receptor-gamma and Peroxisome proliferator-activated receptor-delta genes: a polygenic approach to obesity.
|
18657264 |
2008 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin.
|
15725703 |
2005 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) regulates adipocyte differentiation and lipid deposition, but its role in lipolysis and dysregulation in obesity is not well defined.
|
22310664 |
2012 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Our results suggest that a novel MG derivative, CBMG may have beneficial applications in the control of obesity through the suppression of PPARγ-induced adipocyte differentiation and lipid accumulation.
|
28625492 |
2017 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
The causes of obesity are multifactorial but may include dysregulation of a family of related genes, such as the peroxisome proliferator activated receptor gamma (PPARgamma).
|
18855061 |
2009 |
|
Obesity
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Obesity
|
1.000 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor γ (PPARγ) ligands are therapeutic agents used in patient with Type 2 diabetes and obesity which have recently been studied for their potential anti-tumor effect.
|
23254958 |
2013 |